U.S. Marine and Shipping Stock News

Viewing insider transactions for Candel Therapeutics, Inc.'s ( NASDAQ:CADL ) over the last year, we see that insiders...

Earlier this week, Jefferies analysts said Take-Two Interactive’s upcoming fiscal first-quarter update is expected to be broadly in line, but investors are primarily watching for any management commentary on the timing and scope of Grand Theft Auto VI. The key insight is that expectations and uncertainty around GTA VI, especially its online component, are now more influential for sentiment than near-term quarterly performance. We’ll now examine how this heightened focus on GTA VI’s launch...

The new 25% US tariff on a broad range of Brazilian imports puts fresh attention on US Domestic Manufacturing stocks that could see shifts in demand, costs, or competitive positioning as supply chains adjust. With key Brazilian exports like coffee, beef, orange juice, and aircraft parts exempt, the impact is focused on other areas where domestic producers might gain or face new pressures. This article walks through 3 stocks from the US Domestic Manufacturing screener that appear positively...

Looking at Anteris Technologies Global Corp.'s ( NASDAQ:AVR ) insider transactions over the last year, we can see that...

Some Tower Semiconductor Ltd. ( NASDAQ:TSEM ) shareholders may be a little concerned to see that the CEO & Director...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

In recent days, Arm Holdings has been swept up in a global semiconductor pullback, as sector-wide worries over AI-fueled valuations, export controls, and rising competition have pressured chip and AI-infrastructure stocks across Asia, Europe, and the U.S. At the same time, Arm’s push into data-center AI CPUs, its expanding AGI CPU customer list, and questions around enforcing export restrictions to China have sharpened the focus on how resilient its licensing and royalty model may be under...

Immunome (IMNM) is in focus after the FDA accepted its New Drug Application for varegacestat, an oral therapy for adults with desmoid tumors, supported by positive Phase 3 RINGSIDE trial data. See our latest analysis for Immunome. The FDA’s acceptance of Immunome’s NDA comes after a mixed period for the stock, with a 20.45% 1 month share price return but a 9.38% decline over three months. The 1 year total shareholder return of 110.96% points to strong longer term momentum. If this kind of...

UroGen Pharma (URGN) is back in focus after the FDA cleared its Investigational New Drug application for UGN-501, allowing the company to move ahead with a Phase 1 bladder cancer study. See our latest analysis for UroGen Pharma. Against this backdrop, UroGen Pharma’s share price has climbed strongly, with a 30-day share price return of 22.62% and a 90-day share price return of 78.48%, while the 1-year total shareholder return of 163.46% points to powerful momentum rather than a short-lived...

Halliburton (NYSE:HAL) has secured multi-year contracts from Saudi Aramco covering unconventional gas development and onshore oil activities. The work includes deployment of Saudi Arabia’s first intelligent fracturing platform as part of a major unconventional gas project. The agreements also span a multi-year integrated oilfield program across hundreds of planned wells. Halliburton will expand local manufacturing and workforce commitments to support these projects. For investors watching...

ArcBest (ARCB) has moved into focus after announcing a restructuring plan that includes a 2% workforce reduction, the closing of ten ABF Freight service centers, the consolidation of brands, and the booking of sizeable cash charges and non cash impairments. See our latest analysis for ArcBest. The restructuring news comes after a period of strong momentum for ArcBest, with the share price at $159.81 and a 90 day share price return of 34.7%, while the 1 year total shareholder return is...

Cousins Properties (CUZ) has drawn fresh attention after recent trading, with the stock closing at $31.76 and showing double digit gains over both the past month and the past three months. See our latest analysis for Cousins Properties. The recent share price move in Cousins Properties builds on stronger momentum, with a 30 day share price return of 14.62% and a 90 day share price return of 31.84%, alongside a 1 year total shareholder return of 18.07%. If recent gains in Cousins Properties...

ANI Pharmaceuticals has delivered a strong 139.1% return over the past 5 years, yet at around US$79.20 the valuation checks now suggest the stock is closer to fairly priced than obviously cheap. A 139.1% total return over 5 years indicates ANI Pharmaceuticals has already rewarded patient shareholders, so fresh buyers may be weighing how much of the story is reflected in the current price. Positive topline data from the SYNCHRONICITY trial can support expectations for the branded portfolio,...

The Fed’s renewed hawkish tone, paired with volatile energy prices and a firm labor market, is reshaping how investors think about interest rate risk. For U.S. regional banks, tighter policy can shift the balance between what they earn on loans and what they pay on deposits, while swings in inflation expectations influence funding costs and credit demand. This article uses a focused screener of mid sized lenders to highlight 3 regional bank stocks whose business profiles could be especially...

Bell Canada has completed its first direct to device satellite ground station to support AST SpaceMobile's network in Canada. AST SpaceMobile secured new regulatory approval in New Zealand, expanding its potential service footprint. The company is preparing for the launch of additional BlueBird satellites to build out its direct to device constellation. AST SpaceMobile (NasdaqGS:ASTS) is back in focus as it adds fresh infrastructure and regulatory pieces to its direct to device puzzle. The...

DoorDash (NasdaqGS:DASH) is seeking approval in New Mexico to deploy its autonomous delivery vehicle, Dot, for short-distance deliveries. The company is pursuing legislative changes that would allow these robots to operate on public roads across the state. The outcome could influence how quickly DoorDash rolls out similar technology in additional U.S. jurisdictions. DoorDash is best known for its food delivery platform, and the push to deploy Dot in New Mexico highlights how the company is...

Prudential Financial (PRU) is in the spotlight after reporting stronger than expected first quarter earnings, with firmer investment income, solid annuity and retirement demand, and management underscoring ongoing business transformation and retirement focused product expansion. See our latest analysis for Prudential Financial. The stronger first quarter update has arrived alongside a clear pick up in momentum, with Prudential Financial’s 30 day share price return of 11.27% and 90 day share...

Corcept Therapeutics has delivered very strong long term share price gains over the past five years, yet its latest valuation checks lean more cautious, leaving investors weighing a powerful performance track record against a weak overall value score. Corcept Therapeutics is up about 346.1% over five years, which puts the recent share price in the context of a very strong run already behind it. Progress with cortisol modulating drugs, including Lifyorli and the resubmitted relacorilant...

Geopolitics just moved back to the front of the market’s attention, with U.S. strikes on Iran, drone and missile attacks across the Gulf, and oil prices reacting sharply. When tensions spill into shipping lanes and supply chains, some stocks can gain new contracts or attention, while others face higher risks and costs. This article looks at how that mix of risk and opportunity connects to the latest Defense and Aerospace Stocks screener and highlights 3 stocks that appear positively exposed...

Arrowhead Pharmaceuticals (ARWR) has drawn investor attention after recent share price moves, with the stock up about 4.1% over the past day but down roughly 8.3% over the past month. See our latest analysis for Arrowhead Pharmaceuticals. The recent 1 day share price return of 4.1% comes after a softer 30 day share price return of 8.3% and a 9.6% share price return year to date. The 1 year total shareholder return of very large magnitude suggests Arrowhead Pharmaceuticals has already...

Bitdeer Technologies Group has broken ground on a new 187,000-square-foot advanced electronics manufacturing facility in Sparks, Nevada, marking a US$36 million move into domestic production of its SEALMINER computing hardware and creating 70 local jobs. This facility, set to augment Bitdeer’s existing U.S. data centers and innovation hub, signals a deeper commitment to U.S.-based, vertically integrated computing hardware manufacturing within Nevada’s growing tech ecosystem. Next, we’ll...

Abbott Laboratories (ABT) just posted Q2 2026 revenue of about US$12.6b with basic EPS of US$0.53, alongside trailing twelve month revenue of roughly US$46.6b and EPS of US$3.11. Over recent quarters the company has seen revenue move from about US$11.1b in Q2 2025 to US$12.6b in Q2 2026, while quarterly EPS shifted from US$1.02 to US$0.53. This sets up a results season where investors are likely to focus closely on how margins are holding up in the current mix of growth drivers. See our full...

AI trading signals put Kirby in focus Fresh AI generated trading signals around Kirby (KEX) have pushed the stock into the spotlight, with the models flagging neutral near and mid term readings, as well as a long term strong positive bias. The same signals highlight a mid channel oscillation pattern and outline a short setup with defined downside potential and limited indicated risk, along with suggested institutional style long, breakout, and hedging approaches. See our latest analysis for...

Palantir Technologies (PLTR) is back in focus after a series of AI focused partnerships and government wins, including new work with the U.S. Small Business Administration and enterprise clients across insurance and cloud infrastructure. See our latest analysis for Palantir Technologies. Despite the stream of new AI partnerships and government work, Palantir Technologies’ share price has been under pressure, with the stock down 21.14% on a year to date share price return and the 1 year total...